We thank all the study participants and the Baney city and Rebola community authorities for their cooperation; the safety monitoring board, chaired by Kent Kester, with Alan Cross, Alberto Garcia-Basteiro, and the local safety monitor Feliciano P. Shumad serving as four physician members; Haidar Haj and Shilo Yaari (physicians from La Paz Medical Center, Malabo); Aaron Cohen (pharmacist from La Paz Medical Center, Malabo); Hassan Abuleil, Antonio E. Roca and Gema R. Masela (nurses from La Paz Medical Center, Malabo), Fares Awwad and Adi Katz (laboratory technicians from La Paz Medical Center, Malabo) and Victor Mba (MCDI community liaison officer) for their invaluable support. We are grateful to Mrs. Y. Ovadia and Dr. M. Averbuch for establishing at the start of this project and the involvement of La Paz Medical Center in providing the clinical and infrastructure support for this clinical trial. We thank the Sanaria and Protein Potential teams for manufacture and shipping of investigational products, PfSPZ Vaccine and diluents, regulatory, quality, and clinical site activities, and legal and administrative support, including especially D. Padilla Cheney, A. Eappen, T. Li, Y. Wu, A. Awe, M. Orozco, A. Patil, A. Gunasekera, Y. Wen, K. Nelson, J. Overby, S. Matheny, V. Pich, B. Jiang, L. Gao, R. Xu, T. T. Wai, S. Monsheimer, P. De La Vega, H. Huang, J. Jackson, F. Beams, R. Douglas, R. C. Thompson, D. Dolberg, and A. Hoffman.
World Health Organization, 2016. World Malaria Report 2016. Geneva, Switzerland: World Health Organization.
World Health Organization, 2015. Global Technical Strategy for Malaria 2016–2030. Geneva, Switzerland: World Health Organization.
RTSS Clinical Trials Partnership, 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 31–45.
RTS,S Clinical Trials Partnership, 2014. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11: e1001685.
Seder RA VRC 312 Study Team, 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 1359–1365.
Sissoko MS 2017. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17: 498–509.
Lyke KE 2017. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA 114: 2711–2716.
Kleinschmidt I, Sharp B, Benavente LE, Schwabe C, Torrez M, Kuklinski J, Morris N, Raman J, Carter J, 2006. Reduction in infection with Plasmodium falciparum one year after the introduction of malaria control interventions on Bioko Island, Equatorial Guinea. Am J Trop Med Hyg 74: 972–978.
Hoffman SL 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97–106.
Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf. Accessed May 2, 2017.
Cohee LM, Kalilani-Phiri L, Mawindo P, Joshi S, Adams M, Kenefic L, Jacob CG, Taylor TE, Laufer MK, 2016. Parasite dynamics in the peripheral blood and the placenta during pregnancy-associated malaria infection. Malar J 15: 483.
Roestenberg M 2013. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88: 5–13.
Shekalaghe S 2014. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 91: 471–480.
Gómez-Pérez GP 2015. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J 14: 306.
Mordmüller B 2015. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 14: 117.
Bastiaens GJ 2016. Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg 94: 663–673.
Kilian HD, Nielsen G, 1989. Cell-mediated and humoral immune responses to BCG and rubella vaccinations and to recall antigens in onchocerciasis patients. Trop Med Parasitol 40: 445–453.
Da’Dara AA, Lautsch N, Dudek T, Novitsky V, Lee TH, Essex M, Harn DA, 2006. Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice. Vaccine 24: 5211–5219.
Esen M 2012. Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine 30: 7621–7624.
Kolbaum J, Tartz S, Hartmann W, Helm S, Nagel A, Heussler V, Sebo P, Fleischer B, Jacobs T, Breloer M, 2012. Nematode-induced interference with the anti-Plasmodium CD8+ T-cell response can be overcome by optimizing antigen administration. Eur J Immunol 42: 890–900.
Apiwattanakul N, Thomas PG, Iverson AR, McCullers JA, 2014. Chronic helminth infections impair pneumococcal vaccine responses. Vaccine 32: 5405–5410.
Noland GS, Chowdhury DR, Urban JF Jr, Zavala F, Kumar N, 2010. Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice. Vaccine 28: 2917–2923.